{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:52:48Z","timestamp":1789523568010,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.bmc.2017.06.007","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T22:16:24Z","timestamp":1497046584000},"page":"4175-4193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus"],"prefix":"10.1016","volume":"25","author":[{"given":"Hideki","family":"Hirose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Mizojiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Tamura-Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Muraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sugama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1375-5069","authenticated-orcid":false,"given":"Akito","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuo","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2017.06.007_b0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5001\/omj.2012.68","article-title":"Type 2 diabetes mellitus: a review of current trends","volume":"27","author":"Olokoba","year":"2012","journal-title":"Oman Med J"},{"key":"10.1016\/j.bmc.2017.06.007_b0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bmc.2017.06.007_b0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/cpt.144","article-title":"The current drug treatment landscape for diabetes and perspectives for the future","volume":"98","author":"Bailey","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bmc.2017.06.007_b0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.179.4068.77","article-title":"Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone","volume":"179","author":"Brazeau","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.bmc.2017.06.007_b0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0165-6147(96)01032-2","article-title":"Somatostatin: the neuroendocrine story","volume":"18","author":"Gillies","year":"1997","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bmc.2017.06.007_b0030","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1046\/j.1365-2826.1997.00650.x","article-title":"Somatostatin plays a dual, stimulatory\/inhibitory role in the control of growth hormone secretion by two somatotrope subpopulations from porcine pituitary","volume":"9","author":"Ram\u00edrez","year":"1997","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.bmc.2017.06.007_b0035","doi-asserted-by":"crossref","first-page":"E311","DOI":"10.1152\/ajpendo.00434.2001","article-title":"Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures","volume":"283","author":"Chisholm","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.bmc.2017.06.007_b0040","first-page":"G983","article-title":"Somatostatin receptor subtype-5 mediates inhibition of peptide YY secretion from rat intestinal cultures","volume":"279","author":"Chisholm","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.bmc.2017.06.007_b0045","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00210-004-0992-8","article-title":"Role of somatostatin receptors on gastric acid secretion in wild-type and somatostatin receptor type 2 knockout mice","volume":"370","author":"Pigueras","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bmc.2017.06.007_b0050","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/db08-1534","article-title":"Regulating glucagon secretion: somatostatin in the spotlight","volume":"58","author":"Rutter","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.bmc.2017.06.007_b0055","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1210\/me.2001-0035","article-title":"Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis","volume":"17","author":"Strowski","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.bmc.2017.06.007_b0060","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/db08-0792","article-title":"Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function","volume":"58","author":"Hauge-Evans","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.bmc.2017.06.007_b0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/B978-0-12-800174-5.00007-7","article-title":"The somatostatin receptor in human pancreatic \u03b2-cells","volume":"95","author":"Braun","year":"2014","journal-title":"Vitam Horm"},{"key":"10.1016\/j.bmc.2017.06.007_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0005-2736(03)00235-9","article-title":"Somatostatin receptors","volume":"1616","author":"M\u00f8llera","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bmc.2017.06.007_b0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1196\/annals.1294.012","article-title":"Molecular signaling of somatostatin receptors","volume":"1014","author":"Lahlou","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bmc.2017.06.007_b0080","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JME-11-0121","article-title":"Molecular mechanisms of somatostatin receptor trafficking","volume":"48","author":"Csaba","year":"2012","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.bmc.2017.06.007_b0085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jss.2005.05.024","article-title":"The effect of global SSTR5 gene ablation on the endocrine pancreas and glucose regulation in aging mice","volume":"129","author":"Wang","year":"2005","journal-title":"J Surg Res"},{"key":"10.1016\/j.bmc.2017.06.007_b0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2337\/db11-0690","article-title":"Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counter regulatory responses to hypoglycemia in streptozotocin-induced diabetic rats","volume":"61","author":"Yue","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.bmc.2017.06.007_b0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.regpep.2009.09.006","article-title":"Novel, non-peptidic somatostatin receptor subtype 5 antagonists improve glucose tolerance in rodents","volume":"159","author":"Sprecher","year":"2010","journal-title":"Regul Pept"},{"key":"10.1016\/j.bmc.2017.06.007_b0100","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1021\/jm701143p","article-title":"Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach","volume":"50","author":"Martin","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.06.007_b0105","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.1021\/jm701144e","article-title":"From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling","volume":"50","author":"Guba","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.06.007_b0110","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1016\/j.bmcl.2009.09.024","article-title":"Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists","volume":"19","author":"Martin","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2017.06.007_b0115","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1016\/j.bmcl.2010.06.026","article-title":"Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists","volume":"20","author":"Alker","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2017.06.007_b0120","doi-asserted-by":"crossref","first-page":"12329","DOI":"10.1073\/pnas.210244497","article-title":"A structural basis for drug-induced long QT syndrome","volume":"97","author":"Mitcheson","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2017.06.007_b0125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrd1108","article-title":"The impact of drug-induced QT interval prolongation on drug discovery and development","volume":"2","author":"Fermini","year":"2003","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.bmc.2017.06.007_b0130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1359-6446(04)03278-7","article-title":"Predictive in silico modeling for hERG channel blockers","volume":"10","author":"Aronov","year":"2005","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bmc.2017.06.007_b0135","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.ejmech.2007.12.025","article-title":"Identification of \u201ctoxicophoric\u201d features for predicting drug-induced QT interval prolongation","volume":"43","author":"Coi","year":"2008","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2017.06.007_b0140","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1021\/jm801236n","article-title":"Docking model of drug binding to the human ether-\u00e0-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach","volume":"52","author":"Imai","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.06.007_b0145","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1248\/cpb.c13-00436","article-title":"Impact of physicochemical profiling for rational approach on drug discovery","volume":"61","author":"Nakashima","year":"2013","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.bmc.2017.06.007_b0150","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1021\/jm060379l","article-title":"Medicinal chemistry of hERG optimizations: highlights and hang-ups","volume":"49","author":"Jamieson","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.06.007_b0155","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1016\/j.bmcl.2006.08.039","article-title":"Inhibitory effect of carboxylic acid group on hERG binding","volume":"16","author":"Zhu","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2017.06.007_b0160","series-title":"Molecular Operating Environment (MOE), 2012.10","year":"2012"},{"key":"10.1016\/j.bmc.2017.06.007_b0165","unstructured":"Ricerca Biosciences, LLC, Taipei, Taiwan, http:\/\/www.ricerca.com."},{"key":"10.1016\/j.bmc.2017.06.007_b0170","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from flatland: increasing saturation as an approach to improving clinical success","volume":"52","author":"Lovering","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.06.007_b0175","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1248\/yakushi1947.115.3_213","article-title":"Studies of novel 1,4-dihydropyridine Ca antagonist CS-905. I. Measurement of partition coefficient (log P) by high performance liquid chromatography (HPLC)","volume":"115","author":"Masumoto","year":"1995","journal-title":"Yakugaku Zasshi"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089617309525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089617309525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:51:28Z","timestamp":1760835088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089617309525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":35,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0968089617309525"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2017.06.007","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2017.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}